Chronic pain is a major healthcare problem in Europe and one that many experts believe needs to be taken more seriously.
It has been estimated that chronic pain of moderate to severe intensity occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives.¹ Despite the scale of the problem, few patients are managed by pain specialists and many receive inadequate pain management.¹
The type of pain arising from damage or dysfunction of the nervous system (neuropathic pain) is an area of growing focus for Astellas. Neuropathic pain, which sufferers often describe as burning or stabbing, can overwhelm peoples’ lives and many patients have to compromise between pain relief and the side effects of medications. Treatments for neuropathic pain, nociceptive pain and diabetic neuropathy are under investigation in our pipeline.
1. Breivik H, Collett B, Ventafridda V, Choen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287-333.
Learn more about our therapy areas:
Innovative therapies in preventing organ rejection after transplantation
World-leading approach in R&D to satisfy unmet patient needs in urological conditions
Our commitment is to developing first-in-class and best-in-class therapies
Addressing the complex challenges of serious fungal and bacterial infections
Pioneering treatments that effectively manage chronic pain